These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

385 related articles for article (PubMed ID: 26980848)

  • 1. Simultaneous early-onset immune thrombocytopenia and autoimmune thyroid disease following alemtuzumab treatment in relapsing-remitting multiple sclerosis.
    Obermann M; Ruck T; Pfeuffer S; Baum J; Wiendl H; Meuth SG
    Mult Scler; 2016 Aug; 22(9):1235-41. PubMed ID: 26980848
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alemtuzumab-induced red cell aplasia and other immune cytopenias: not so 'pure'.
    Aitken L; Patel R; D'Rozario J; Choi P
    Immunotherapy; 2022 Feb; 14(2):95-99. PubMed ID: 34743591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of immune thrombocytopenia in multiple sclerosis patients treated with alemtuzumab: a Belgian consensus.
    Lambert C; Dubois B; Dive D; Lysandropoulos A; Selleslag D; Vanopdenbosch L; Van Pesch V; Vanwijmeersch B; Janssens A
    Acta Neurol Belg; 2018 Mar; 118(1):7-11. PubMed ID: 29380254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte pharmacodynamics are not associated with autoimmunity or efficacy after alemtuzumab.
    Wiendl H; Carraro M; Comi G; Izquierdo G; Kim HJ; Sharrack B; Tornatore C; Daizadeh N; Chung L; Jacobs AK; Hogan RJ; Wychowski LV; Van Wijmeersch B;
    Neurol Neuroimmunol Neuroinflamm; 2020 Jan; 7(1):. PubMed ID: 31662412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A distinctive form of immune thrombocytopenia in a phase 2 study of alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.
    Cuker A; Coles AJ; Sullivan H; Fox E; Goldberg M; Oyuela P; Purvis A; Beardsley DS; Margolin DH
    Blood; 2011 Dec; 118(24):6299-305. PubMed ID: 21960587
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.
    ; Coles AJ; Compston DA; Selmaj KW; Lake SL; Moran S; Margolin DH; Norris K; Tandon PK
    N Engl J Med; 2008 Oct; 359(17):1786-801. PubMed ID: 18946064
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiac sarcoidosis requiring ICD placement and immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis.
    Erlich-Malona N; Cahill J; Chaudhry S; Martin J; Rizvi S
    Mult Scler Relat Disord; 2021 Jan; 47():102599. PubMed ID: 33160137
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune thrombocytopenia in alemtuzumab-treated MS patients: Incidence, detection, and management.
    Cuker A; Bass AD; Nadj C; Agius MA; Steingo B; Selmaj KW; Thoits T; Guerreiro A; Van Wijmeersch B; Ziemssen T; Meuth SG; LaGanke CC; Thangavelu K; Rodriguez CE; Baker DP; Margolin DH; Jannsens A
    Mult Scler; 2020 Jan; 26(1):48-56. PubMed ID: 30785358
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
    Coles AJ; Twyman CL; Arnold DL; Cohen JA; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Miller T; Fisher E; Sandbrink R; Lake SL; Margolin DH; Oyuela P; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1829-39. PubMed ID: 23122650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis.
    di Ioia M; Farina D; di Tommaso V; Travaglini D; Pietrolongo E; Onofrj M; de Luca G
    Mult Scler; 2018 May; 24(6):813-815. PubMed ID: 29359617
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immediate transient thrombocytopenia at the time of alemtuzumab infusion in multiple sclerosis.
    Ranganathan U; Kaunzner U; Foster S; Vartanian T; Perumal JS
    Mult Scler; 2018 Apr; 24(4):540-542. PubMed ID: 28287030
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monitoring and management of autoimmunity in multiple sclerosis patients treated with alemtuzumab: practical recommendations.
    Devonshire V; Phillips R; Wass H; Da Roza G; Senior P
    J Neurol; 2018 Nov; 265(11):2494-2505. PubMed ID: 29525836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vitiligo after alemtuzumab treatment: Secondary autoimmunity is not all about B cells.
    Ruck T; Pfeuffer S; Schulte-Mecklenbeck A; Gross CC; Lindner M; Metze D; Ehrchen J; Sondermann W; Pul R; Kleinschnitz C; Wiendl H; Meuth SG; Klotz L
    Neurology; 2018 Dec; 91(24):e2233-e2237. PubMed ID: 30404783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early neutropenia with thrombocytopenia following alemtuzumab treatment for multiple sclerosis: case report and review of literature.
    Maniscalco GT; Cerillo I; Servillo G; Napolitano M; Guarcello G; Abate V; Improta G; Florio C
    Clin Neurol Neurosurg; 2018 Dec; 175():134-136. PubMed ID: 30419425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial.
    Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA;
    Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autoimmune storm following alemtuzumab.
    Chan C; Beauchemin P; Sayao AL; Carruthers M
    BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35760506
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thyroid disorders in alemtuzumab-treated multiple sclerosis patients: a Belgian consensus on diagnosis and management.
    Decallonne B; Bartholomé E; Delvaux V; D'haeseleer M; El Sankari S; Seeldrayers P; Van Wijmeersch B; Daumerie C
    Acta Neurol Belg; 2018 Jun; 118(2):153-159. PubMed ID: 29372482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab for multiple sclerosis: Long term follow-up in a multi-centre cohort.
    Willis MD; Harding KE; Pickersgill TP; Wardle M; Pearson OR; Scolding NJ; Smee J; Robertson NP
    Mult Scler; 2016 Aug; 22(9):1215-23. PubMed ID: 26514979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod-induced immune thrombocytopenic purpura (ITP).
    Mukharesh L; Rothstein TL
    Clin Neurol Neurosurg; 2020 Oct; 197():106081. PubMed ID: 32739722
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of Autoimmune Thyroid Disease in Multiple Sclerosis Patients Post-Alemtuzumab Improves Treatment Response.
    Sovetkina A; Nadir R; Scalfari A; Tona F; Murphy K; Rigoni E; Dorsey R; Malik O; Nandoskar A; Singh-Curry V; Nicholas R; Martin N
    J Clin Endocrinol Metab; 2020 Sep; 105(9):. PubMed ID: 32667988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.